BAYER has signed an agreement
with Compugen worth up to
US$540 million for the research,
development and marketing of
cancer immunotherapy drugs.
The companies will undertake
a preclinical research program,
with Bayer to have full control
over further development and
worldwide commercialisation.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.